UCB and Dermira have entered into an exclusive pharma licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.
This collaboration aims to broaden patient access to Cimzia and make it available to patients with psoriasis, a chronic autoimmune disorder.
Cimzia is not currently approved for the treatment of psoriasis by any regulatory authority.
UCB grants Dermira an exclusive license to develop certolizumab pegol in psoriasis in the US, Canada and the European Union.
Dermira will be responsible for Phase 3 development costs and will receive payments of up to $49.5 million on the achievement of development and regulatory milestones.
Subject to regulatory approval of Cimzia in psoriasis, Dermira is granted an exclusive commercial license to market Cimzia to dermatologists in the US and Canada.
UCB will record the sales and Dermira will receive tiered royalty payments on those product sales which are attributable to dermatologists in the US and Canada and up to $40 million upon the achievement of tiered commercial milestones.
In support of the partnership, UCB has made a $5 million equity investment in Dermira and a commitment to invest up to an additional $15 million in future Dermira equity financings.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with UCB
Read: more on UCB company profile, recent partnering, M&A and financing news and articles
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity